CoChat

Moclobemide in Social Phobia: A Controlled Dose-Response Trial

Noyes, Russell Jr, Moroz, Georges, Davidson, Jonathan R.T., Liebowitz, Michael R., Davidson, Arnold, Siegel, Judith, Bell, Jon, Cain, John W., Curlik, Sharon M., Kent, Thomas A., Lydiard, R. Bruce, Mallinger, Alan G., Pollack, Mark H., Rapaport, Mark, Rasmussen, Steven A., Hedges, Dawson, Schweizer, Edward, Uhlenhuth, Eberhard H. · 1997 · Journal of Clinical Psychopharmacology
Cited by 149

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35% of subjects on 900 mg of moclobemide and 33% of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-199708000-00002

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 149

Metadata

Authors
Noyes, R. J., Moroz, G., Davidson, J. R. T., Liebowitz, M. R., Davidson, A., Siegel, J., Bell, J., Cain, J. W., Curlik, S. M., Kent, T. A., Lydiard, R. B., Mallinger, A. G., Pollack, M. H., Rapaport, M., Rasmussen, S. A., Hedges, D., Schweizer, E., & Uhlenhuth, E. H.
Venue
Journal of Clinical Psychopharmacology
Published
1997-08
Volume
17
Issue
4
Pages
247-254
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2058514732
Cited by
149
References
4
FWCI
24.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moclobemide in Social Phobia: A Controlled Dose-Response Trial. https://app.cochat.ai/papers/10.1097/00004714-199708000-00002
The paper
Noyes, R. J., Moroz, G., Davidson, J. R. T., Liebowitz, M. R., Davidson, A., Siegel, J., Bell, J., Cain, J. W., Curlik, S. M., Kent, T. A., Lydiard, R. B., Mallinger, A. G., Pollack, M. H., Rapaport, M., Rasmussen, S. A., Hedges, D., Schweizer, E., & Uhlenhuth, E. H. (1997). Moclobemide in Social Phobia: A Controlled Dose-Response Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199708000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.